In addition, FGFR4.28HTM.28z CAR exhibited better tumor control than FGFR4.28HTM.BBz CAR in a more aggressive orthotopic model of RMS559 cells (Fig. 1H–K; Supplementary Fig. 3F–G), whereas even 10 million of FGFR4.8HTM.BBz CAR T-cells failed to show therapeutic benefit (Supplementary Fig. 4A–D). This evidence concerns the gene FGFR4 and neoplasm.